Treatment Toxicity: Radiation

Fitzgerald, Thomas J.; Bishop–Jodoin, Maryann; Laurie, Fran; Sacher, Allison; Aghababian, Richard V.; Dickson, Eric W.

doi:10.1007/978-3-319-26387-8_34

Cited by 5 publications

(6 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiation therapy is a highly effective treatment for many types of cancers including lymphoma, breast, lung, neck, and head cancers [ 5 , 301 ]. However, radiation-based cancer treatments can also result in serious cardiotoxic side effects, including pericardial fibrosis, pericardial effusion, and diffuse myocardial fibrosis, all of which can lead to heart failure [ 302 ].…”

Section: Radiation Therapymentioning

confidence: 99%

CYP1B1 as a therapeutic target in cardio-oncology

2020

View full text Add to dashboard Cite

Cardiovascular complications have been frequently reported in cancer patients and survivors, mainly because of various cardiotoxic cancer treatments. Despite the known cardiovascular toxic effects of these treatments, they are still clinically used because of their effectiveness as anti-cancer agents. In this review, we discuss the growing body of evidence suggesting that inhibition of the cytochrome P450 1B1 enzyme (CYP1B1) can be a promising therapeutic strategy that has the potential to prevent cancer treatment-induced cardiovascular complications without reducing their anti-cancer effects. CYP1B1 is an extrahepatic enzyme that is expressed in cardiovascular tissues and overexpressed in different types of cancers. A growing body of evidence is demonstrating a detrimental role of CYP1B1 in both cardiovascular diseases and cancer, via perturbed metabolism of endogenous compounds, production of carcinogenic metabolites, DNA adduct formation, and generation of reactive oxygen species (ROS). Several chemotherapeutic agents have been shown to induce CYP1B1 in cardiovascular and cancer cells, possibly via activating the Aryl hydrocarbon Receptor (AhR), ROS generation, and inflammatory cytokines. Induction of CYP1B1 is detrimental in many ways. First, it can induce or exacerbate cancer treatment-induced cardiovascular complications. Second, it may lead to significant chemo/radio-resistance, undermining both the safety and effectiveness of cancer treatments. Therefore, numerous preclinical studies demonstrate that inhibition of CYP1B1 protects against chemotherapy-induced cardiotoxicity and prevents chemo- and radio-resistance. Most of these studies have utilized phytochemicals to inhibit CYP1B1. Since phytochemicals have multiple targets, future studies are needed to discern the specific contribution of CYP1B1 to the cardioprotective and chemo/radio-sensitizing effects of these phytochemicals.

show abstract

Section: Radiation Therapymentioning

confidence: 99%

CYP1B1 as a therapeutic target in cardio-oncology

2020

View full text Add to dashboard Cite

show abstract

“…1 Systemic therapy and radiotherapy can provide substantial benefit for many patients, but these treatments are also associated with a risk of serious complications. 2,3 Although many of these adverse effects can be managed in the outpatient setting, some are severe enough to require treatment in a hospital. Multiple studies have characterized hospitalizations and admissions for patients with cancer in general [4][5][6][7][8][9] as well as those receiving chemotherapy or radiotherapy.…”

mentioning

confidence: 99%

Treatment-Related Complications of Systemic Therapy and Radiotherapy

et al. 2019

View full text Add to dashboard Cite

IMPORTANCE Systemic therapy and radiotherapy can be associated with acute complications that may require emergent care. However, there are limited data characterizing complications and the financial burden of cancer therapy that are treated in emergency departments (EDs) in the United States.OBJECTIVES To estimate the incidence of treatment-related complications of systemic therapy or radiotherapy, examine factors associated with inpatient admission, and investigate the overall financial burden. DESIGN, SETTING, AND PARTICIPANTSA retrospective analysis of the Healthcare Cost and Utilization Project Nationwide Emergency Department Sample was performed. Between January 2006 and December 2015, there was a weighted total of 1.3 billion ED visits; of these, 1.5 million were related to a complication of systemic therapy or radiotherapy for cancer. Data analysis was conducted from February 22 to December 23, 2018. External cause of injury codes, Clinical Classifications Software,

show abstract

“…The fraction of all cancer survivors who received radiation increased from 24% in 2000 to 29% in 2020 [ 56 ]. Normal tissue toxicity is, however, a limiting factor for receiving sufficient doses of radiation to kill the tumor [ 57 ]. Common radiation toxicities include dermatitis, pneumonitis, myelosuppression, secondary tumors, mucositis, and skin irritation.…”

Section: Radioprotection By Curcuminmentioning

confidence: 99%

Radiosensitization and Radioprotection by Curcumin in Glioblastoma and Other Cancers

et al. 2022

View full text Add to dashboard Cite

Radiation therapy plays an important role in almost every cancer treatment. However, radiation toxicity to normal tissues, mainly due to the generation of reactive free radicals, has limited the efficacy of radiotherapy in clinical practice. Curcumin has been reported to possess significant antitumor properties. Although curcumin can sensitize cancer cells to irradiation, healthy cells are much less sensitive to this effect, and thus, curcumin is thought to be a potent, yet safe anti-cancer agent. In this review, a summary of the role of curcumin as both a radiosensitizer and radioprotector has been presented, based on the most recent data from the experimental and clinical evaluation of curcumin in different cancer cell lines, animal models, and human patients.

show abstract

Treatment Toxicity: Radiation

Cited by 5 publications

References 59 publications

CYP1B1 as a therapeutic target in cardio-oncology

CYP1B1 as a therapeutic target in cardio-oncology

Treatment-Related Complications of Systemic Therapy and Radiotherapy

Radiosensitization and Radioprotection by Curcumin in Glioblastoma and Other Cancers

Contact Info

Product

Resources

About